Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Sequencing strategies in the new treatment landscape of prostate cancer.

Caffo O, Maines F, Kinspergher S, Veccia A, Messina C.

Future Oncol. 2019 Sep;15(25):2967-2982. doi: 10.2217/fon-2019-0190. Epub 2019 Aug 19.

PMID:
31424285
2.

Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.

Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP.

J Urol. 2015 Dec;194(6):1537-47. doi: 10.1016/j.juro.2015.06.106. Epub 2015 Jul 18. Review.

PMID:
26196735
3.

Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.

Damodaran S, Lang JM, Jarrard DF.

J Urol. 2019 May;201(5):876-885. doi: 10.1097/JU.0000000000000117. Review.

PMID:
30747897
4.

Current management of advanced and castration resistant prostate cancer.

Gomella LG, Petrylak DP, Shayegan B.

Can J Urol. 2014 Apr;21(2 Supp 1):1-6.

5.

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.

Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, Sonpavde G, Sternberg CN, Yegnasubramanian S, Antonarakis ES.

Eur Urol. 2019 Jan;75(1):88-99. doi: 10.1016/j.eururo.2018.03.028. Epub 2018 Apr 16. Review.

PMID:
29673712
6.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
7.

Castration-resistant prostate cancer: AUA Guideline.

Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, Lin DW, Lowrance WT, Murad MH, Oh WK, Penson DF, Kibel AS.

J Urol. 2013 Aug;190(2):429-38. doi: 10.1016/j.juro.2013.05.005. Epub 2013 May 9.

PMID:
23665272
8.

Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer.

Shiota M, Eto M.

Int J Urol. 2016 May;23(5):360-9. doi: 10.1111/iju.13091. Epub 2016 Apr 8. Review.

9.

Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.

Crawford ED, Schellhammer PF, McLeod DG, Moul JW, Higano CS, Shore N, Denis L, Iversen P, Eisenberger MA, Labrie F.

J Urol. 2018 Nov;200(5):956-966. doi: 10.1016/j.juro.2018.04.083. Epub 2018 May 3. Review.

PMID:
29730201
10.

Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer.

Francini E, Yip S, Ahmed S, Li H, Ardolino L, Evan CP, Kaymakcalan M, Shaw GK, Kantoff PW, Taplin ME, Alimohamed NS, Joshua AM, Heng DYC, Sweeney CJ.

Clin Genitourin Cancer. 2018 Apr;16(2):130-134. doi: 10.1016/j.clgc.2017.12.012. Epub 2017 Dec 27.

11.

Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.

Fizazi K, Smith MR, Tombal B.

Clin Genitourin Cancer. 2018 Oct;16(5):332-340. doi: 10.1016/j.clgc.2018.07.017. Epub 2018 Jul 24. Review.

12.

Advances in systemic therapies for metastatic castration-resistant prostate cancer.

Pant MK, Abughaban A, Aragon-Ching JB.

Future Oncol. 2014 Nov;10(14):2213-26. doi: 10.2217/fon.14.128.

PMID:
25471035
13.

Abiraterone acetate to treat metastatic castration-resistant prostate cancer in combination with prednisone.

Duarte C, Jimeno A, Kessler ER.

Drugs Today (Barc). 2019 Jan;55(1):5-15. doi: 10.1358/dot.2019.55.1.2914339. Review.

PMID:
30740608
14.

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.

Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, Ivashchenko P, Demirhan E, Modelska K, Phung, Krivoshik A, Sternberg CN.

N Engl J Med. 2018 Jun 28;378(26):2465-2474. doi: 10.1056/NEJMoa1800536.

15.

Charting Recent Progress and Challenges in Metastatic Castration-resistant Prostate Cancer: Is There an Optimal Treatment Sequence?

Oudard S, Maroto P, Demonty G, Gerritsen WR.

Eur Urol Focus. 2016 Oct;2(4):426-440. doi: 10.1016/j.euf.2015.11.008. Epub 2015 Dec 24. Review.

PMID:
28723476
16.

Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.

Saad F, Cella D, Basch E, Hadaschik BA, Mainwaring PN, Oudard S, Graff JN, McQuarrie K, Li S, Hudgens S, Lawson J, Lopez-Gitlitz A, Yu MK, Smith MR, Small EJ.

Lancet Oncol. 2018 Oct;19(10):1404-1416. doi: 10.1016/S1470-2045(18)30456-X. Epub 2018 Sep 10.

PMID:
30213449
17.

Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era.

Tucci M, Caffo O, Buttigliero C, Cavaliere C, D'aniello C, Di Maio M, Kinspergher S, Maines F, Rizzo M, Rossetti S, Veccia A, Scagliotti GV, Facchini G.

Cancer Treat Rev. 2019 Mar;74:35-42. doi: 10.1016/j.ctrv.2019.01.002. Epub 2019 Jan 7. Review.

PMID:
30738364
18.

Treatment of Advanced Prostate Cancer.

Teo MY, Rathkopf DE, Kantoff P.

Annu Rev Med. 2019 Jan 27;70:479-499. doi: 10.1146/annurev-med-051517-011947.

19.

Current therapeutic options in metastatic castration-resistant prostate cancer.

Ingrosso G, Detti B, Scartoni D, Lancia A, Giacomelli I, Baki M, Carta G, Livi L, Santoni R.

Semin Oncol. 2018 Oct;45(5-6):303-315. doi: 10.1053/j.seminoncol.2018.10.001. Epub 2018 Oct 30. Review.

PMID:
30446166
20.

Advancing therapies in metastatic castration-resistant prostate cancer.

Baciarello G, Gizzi M, Fizazi K.

Expert Opin Pharmacother. 2018 Nov;19(16):1797-1804. doi: 10.1080/14656566.2018.1527312. Epub 2018 Oct 12. Review.

PMID:
30311804

Supplemental Content

Support Center